Perth-based Syngenis Laboratories has unveiled a new artificial intelligence-powered discovery engine, branded Syngenis Discovery, aimed at speeding up the search for novel therapeutic and diagnostic molecules. This platform tackles a key obstacle in biotechnology: pinpointing promising treatments from an astronomical number of potential molecular combinations. The company is leveraging AI to navigate this complexity, promising to accelerate the identification of next-generation therapies.
The biotech firm, operating from Perth, has structured its business across three core areas: manufacturing, discovery, and diagnostics. This integrated approach is designed to support its ambitions in the rapidly evolving field of RNA therapies and beyond. Syngenis positions itself as a player at the nexus of biotechnology and the growing influence of artificial intelligence.
Syngenis Laboratories currently holds the distinction of being Australia's sole commercial manufacturer of custom synthetic DNA and RNA oligonucleotides. This capability serves researchers and biotech entities throughout the Asia-Pacific. While previously focused on research-grade materials, the company indicates a shift towards clinical-grade production, signalling an expansion of its manufacturing operations.
Read More: Perth Lab Makes DNA for New Medicines, Beyond Weight Loss Drugs
The company's expertise in manufacturing next-generation RNA therapies, which require advanced molecular engineering beyond standard synthesis, forms a crucial part of its operational foundation. This manufacturing prowess also underpins its work in diagnostics, gene therapy, and CRISPR applications.
Previously, Syngenis operated its oligonucleotide manufacturing lab in Perth exclusively for research purposes. However, this limitation is reportedly set to change as the company transitions towards clinical-grade sequence production.
